enstilar foam (50mcg+0.5mg)/gr
leo pharma a/s, denmark industriparken 55,, 2750, ballerup, - calcipotriol; betamethasone - foam (ΔΕΡΜΑΤΙΚΟΣ ΑΦΡΟΣ) - (50mcg+0.5mg)/gr - calcipotriol 50mcg; betamethasone 0,5mg - calcipotriol, combinations
foster inh.sol.p (200+6)mcg/dose
chiesi hellas aebe Πλ. Γερουλάνου & Ρένου Πόγγη 1, 17455 Αλιμος Αττικής 210.6179763 - beclometasone dipropionate; formoterol fumarate dihydrate - inh.sol.p (ΔΙΑΛΥΜΑ ΓΙΑ ΕΙΣΠΝΟΗ ΥΠΟ ΠΙΕΣΗ) - (200+6)mcg/dose - beclometasone dipropionate 0,2mg; formoterol fumarate dihydrate 0,006mg - formoterol and beclometasone
foster® nexthaler pd.inh.md (200+6)mcg/εισπνοη
chiesi hellas aebe Πλ. Γερουλάνου & Ρένου Πόγγη 1, 17455 Αλιμος Αττικής 210.6179763 - beclometasone dipropionate; formoterol fumarate dihydrate - pd.inh.md (ΚΟΝΙΣ ΓΙΑ ΕΙΣΠΝΟΗ) - (200+6)mcg/ΕΙΣΠΝΟΗ - beclometasone dipropionate 200mcg; formoterol fumarate dihydrate 6mcg - formoterol and beclometasone
inuvair® inh.sol.p (200+6)mcg/dose
chiesi hellas aebe Πλ. Γερουλάνου & Ρένου Πόγγη 1, 17455 Αλιμος Αττικής 210.6179763 - beclometasone dipropionate; formoterol fumarate dihydrate - inh.sol.p (ΔΙΑΛΥΜΑ ΓΙΑ ΕΙΣΠΝΟΗ ΥΠΟ ΠΙΕΣΗ) - (200+6)mcg/dose - beclometasone dipropionate 0,2mg; formoterol fumarate dihydrate 0,006mg - formoterol and beclometasone
inuvair® nexthaler pd.inh.md (200+6)mcg/εισπνοη
chiesi hellas aebe Πλ. Γερουλάνου & Ρένου Πόγγη 1, 17455 Αλιμος Αττικής 210.6179763 - formoterol fumarate dihydrate; beclometasone dipropionate - pd.inh.md (ΚΟΝΙΣ ΓΙΑ ΕΙΣΠΝΟΗ) - (200+6)mcg/ΕΙΣΠΝΟΗ - formoterol fumarate dihydrate 0,006mcg; beclometasone dipropionate 0,2mcg - formoterol and beclometasone
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium βρωμιούχο - Πνευμονική Νόσος, Χρόνια Αποφρακτική - Φάρμακα αποφρακτικών παθήσεων των αναπνευστικών οδών, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
androxil 2% cutaneous solution
laboratoires bailleul s.a (0000010146) 10-12 avenue pasteur, luxembourg, l-2310 - minoxidil - cutaneous solution - 2% - minoxidil (0038304915) 1,2g - minoxidil
androxil 5% cutaneous solution
laboratoires bailleul s.a (0000010146) 10-12 avenue pasteur, luxembourg, l-2310 - minoxidil - cutaneous solution - 5% - minoxidil (0038304915) 3g - minoxidil
dovobet (50mcg/0.5mg)g gel
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - calcipotriol monohydrate; betamethasone dipropionate - gel - (50mcg/0.5mg)g - calcipotriol monohydrate (8000003525) 52.2ug; betamethasone dipropionate (0005593204) 0.643mg - calcipotriol combinations
dovobet ointment
leo pharma a/s (0000003363) 55 industriparken, ballerup, 2750 - betamethasone dipropionate; calcipotriol hydrate - ointment - betamethasone dipropionate (0005593204) 0,643mg; calcipotriol hydrate (8000002040) 52,2mcg - calcipotriol combinations